Merck & Co., Inc. (MRK) |
|
104.8 0.57 (0.55%)
|
03-24 16:03 |
|
Open: |
104.09 |
Pre. Close: |
104.23 |
|
High:
|
105.01 |
Low:
|
102.44 |
|
Volume:
|
6,658,529 |
Market Cap:
|
266,044(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:05 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 126.68  One year: 131.02 |
| Support: |
Support1: 102.44 Support2: 85.23 |
| Resistance: |
Resistance1: 108.45 Resistance2: 112.18 |
| Pivot: |
106.83 |
| Moving Average: |
MA(5): 104.96 MA(20): 106.93
MA(100): 107.43 MA(250): 96.66 |
| MACD: |
MACD(12,26): -1 Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 14.5 %D(3): 16.4 |
| RSI: |
RSI(14): 42.9 |
| 52-week: |
High: 115.48 Low: 81.63 |
| Average Vol(K): |
3-Month: 8,447 (K) 10-Days: 8,865 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MRK ] has closed above bottom band by 26.5%. Bollinger Bands are 14.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
105.06 - 105.69 |
105.69 - 106.3 |
|
Low:
|
100.95 - 101.69 |
101.69 - 102.4 |
|
Close:
|
103.65 - 104.75 |
104.75 - 105.82 |
|
Company Description |
|
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. |
Headline News |
Mon, 27 Mar 2023
What Makes Merck & Co. (MRK) A Strong Investment? - Yahoo Finance
Sat, 25 Mar 2023
Women's Lacrosse: Merck's career-high lifts Norwich over Falcons ... - norwichathletics.com
Fri, 24 Mar 2023
Merck & Co. Inc. stock rises Friday, still underperforms market - MarketWatch
Fri, 24 Mar 2023
Moody's affirms Merck & Co.'s A1 rating; revises outlook to stable ... - Moody's
Thu, 23 Mar 2023
Merck Presents its Latest Cosmetics Innovations at “in-cosmetics ... - Merck KGaA
Wed, 22 Mar 2023
Merck Biomanufacturing Optimization Sees Major Production Gains - Genetic Engineering & Biotechnology News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
2,540 (M) |
| Shares Float |
2,540 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
77.6 (%) |
|
Shares Short
|
20,550 (K) |
|
Shares Short P.Month
|
17,150 (K) |
Stock Financials |
|
EPS
|
5.53 |
|
EPS Est Next Qtl
|
0.95 |
|
EPS Est This Year
|
3.86 |
|
EPS Est Next Year
|
4.15 |
|
Book Value (p.s.)
|
18.12 |
|
Profit Margin (%)
|
24.4 |
|
Operating Margin (%)
|
34.6 |
|
Return on Assets (ttm)
|
11.9 |
|
Return on Equity (ttm)
|
34.4 |
|
Qtrly Rev. Growth
|
2.2 |
|
Gross Profit (p.s.)
|
16.56 |
|
Sales Per Share
|
23.33 |
|
EBITDA (p.s.)
|
9.58 |
|
Qtrly Earnings Growth
|
-20 |
|
Operating Cash Flow
|
19,090 (M) |
|
Levered Free Cash Flow
|
12,690 (M) |
Stock Valuations |
|
PE Ratio
|
18.95 |
|
PEG Ratio
|
1.4 |
|
Price to Book value
|
5.78 |
|
Price to Sales
|
4.49 |
|
Price to Cash Flow
|
13.94 |
Stock Dividends |
|
Dividend
|
0.73 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.6% |
|
Dividend Pay Date
|
2022-01-06 |
|
Ex-Dividend Date
|
2021-12-13 |
|
Your Ad Here
|
|
